Charles E. Leonard, PharmD, MSCE
Research Assistant Professor of Epidemiology
Dr. Leonard is known for his work in the comparative safety of medical products among disadvantaged and older adult populations, specifically in the areas of drug interactions and drug-induced sudden cardiac arrest. He has served as principal investigator (PI) or co-investigator of grants and contracts on these topics for the past 15 years. In 2015, he was awarded the American Society for Health-System Pharmacists (ASHP) Foundation’s Drug Therapy Research Award for work examining the risk of sudden cardiac arrest among concomitant users of loop diuretics and potassium supplements. In addition to these areas of primary interest, Dr. Leonard has investigated drug-induced bleeding and thrombosis, drug-induced renal disease, drug-induced respiratory disease, instrumental variable and high-dimensional propensity score methods for pharmacoepidemiology, and the trend-in-trend research design for causal inference, among many other topics.
Dr. Leonard also is devoted to improving outpatient medication use within Penn Medicine. As senior manager of a related clinical program, he leads a health-system-wide initiative to reduce potentially inappropriate medication use among older adults in the ambulatory care setting.
In addition to his roles in the DBEI and the Center for Clinical Epidemiology and Biostatistics, Dr. Leonard serves on the faculty and executive committee of the Center for Pharmacoepidemiology Research and Training (CPeRT), as a faculty member of the Institute for Translational Medicine and Therapeutics (ITMAT), as a core faculty member in the Center for Therapeutic Effectiveness Research (CTER), as senior fellow of the Leonard Davis Institute of Health Economics (LDI), and as fellow of the Institute on Aging (IOA)―all at the University of Pennsylvania. He is a special government employee of the U.S. Food and Drug Administration (FDA) and a council member of the Board of Pharmacy Specialties (BPS). Dr. Leonard also co-leads the Applied Surveillance Core for the FDA’s Sentinel program coordinated by Harvard University. He is an executive editor of the British Journal of Clinical Pharmacology and associate editor of the journals BMC Pharmacology and Toxicology and Pharmacoepidemiology and Drug Safety.
Content Area Specialties
Pharmacoepidemiology, comparative safety, drug interactions, sudden cardiac arrest, type 2 diabetes mellitus
High-dimensional propensity scores, self-controlled case series design, trend-in-trend design